Mavorixafor is under clinical development by X4 Pharmaceuticals and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mavorixafor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mavorixafor overview

Mavorixafor (X4P-001) is under development for the treatment of severe congenital neutropenia, Waldenstrom’s Macroglobulinemia, WHIM syndrome, melanoma and refractory solid tumors including clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer. It is administered through oral route. The drug candidate was under development for the treatment of human immunodeficiency virus (HIV) Infections (AIDS). The drug candidate acts by targeting C-X-C receptor type 4 (CXCR4).

X4 Pharmaceuticals overview

X4 Pharmaceuticals, formerly Arsanis, is a clinical stage bio pharmaceutical company that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of Warts, Hypogammaglobulinemia, Immunodeficiency and Myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI’s). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation of the CXCL12/CXCR4 pathway that enables trafficking of immune cells and effective immunosurveillance. X4 is headquartered in Cambridge, Massachusetts, the US..

For a complete picture of Mavorixafor’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.